PolyPid (NASDAQ:PYPD) Rating Increased to Hold at Wall Street Zen

PolyPid (NASDAQ:PYPD) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Other analysts have also issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of PolyPid in a research report on Wednesday, October 8th. Roth Capital lowered their target price on PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a report on Wednesday, August 13th. Finally, Craig Hallum reiterated a “buy” rating and set a $13.00 price objective (down previously from $15.00) on shares of PolyPid in a report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, PolyPid presently has a consensus rating of “Moderate Buy” and an average target price of $12.40.

PolyPid Trading Up 0.3%

Shares of NASDAQ PYPD opened at $3.59 on Friday. PolyPid has a twelve month low of $2.30 and a twelve month high of $3.93. The company has a market capitalization of $57.08 million, a price-to-earnings ratio of -1.20 and a beta of 1.53. The firm has a 50-day moving average of $3.49 and a two-hundred day moving average of $3.36.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.17. As a group, research analysts predict that PolyPid will post -1.79 earnings per share for the current year.

Institutional Trading of PolyPid

Several large investors have recently bought and sold shares of PYPD. BNP Paribas Financial Markets increased its holdings in PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after purchasing an additional 3,500 shares in the last quarter. Lumbard & Kellner LLC bought a new position in PolyPid in the second quarter worth approximately $135,000. Finally, AIGH Capital Management LLC grew its holdings in shares of PolyPid by 13.6% during the first quarter. AIGH Capital Management LLC now owns 940,381 shares of the company’s stock valued at $2,548,000 after buying an additional 112,514 shares during the last quarter. 26.47% of the stock is owned by institutional investors and hedge funds.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.